"Buprenorphine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.
| Descriptor ID |
D002047
|
| MeSH Number(s) |
D03.132.577.249.150 D03.605.497.150 D03.633.400.686.150 D04.615.723.795.150
|
| Concept/Terms |
Subutex- Subutex
- Buprex
- Temgesic
- Temgésic
6029-M- 6029-M
- 6029 M
- 6029M
- RX-6029-M
- RX 6029 M
- RX6029M
|
Below are MeSH descriptors whose meaning is more general than "Buprenorphine".
Below are MeSH descriptors whose meaning is more specific than "Buprenorphine".
This graph shows the total number of publications written about "Buprenorphine" by people in this website by year, and whether "Buprenorphine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2013 | 2 | 1 | 3 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 0 | 1 |
| 2017 | 3 | 2 | 5 |
| 2018 | 3 | 0 | 3 |
| 2019 | 5 | 0 | 5 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 0 | 2 |
| 2022 | 8 | 0 | 8 |
| 2023 | 3 | 0 | 3 |
| 2024 | 4 | 2 | 6 |
| 2025 | 1 | 2 | 3 |
| 2026 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Buprenorphine" by people in Profiles.
-
Buprenorphine for Cancer Pain: Evidence, Guidelines, and Clinical Rationale for Early Use. J Natl Compr Canc Netw. 2026 Jun; 24(6).
-
High-Dose Buprenorphine Initiation to Rapidly Transition From High-Dose Methadone in the Hospital. Subst Use Addctn J. 2026 Jul; 47(3):917-922.
-
Initiation, retention, and discontinuation of extended-release buprenorphine (BUP-XR) for opioid dependence: A single-arm multi-site trial in Ukraine. Int J Drug Policy. 2026 02; 148:105107.
-
Implementing incentives in family medicine for opioid use disorder treatment: a qualitative inquiry on provider and patient preferences for a low magnitude reward program compatible with buprenorphine treatment. Addict Sci Clin Pract. 2025 12 22; 20(1):97.
-
Barriers to accessing medications for opioid use disorder among rural individuals. Int J Drug Policy. 2025 06; 140:104805.
-
Barriers to Universal Availability of Medications for Opioid Use Disorder in US Jails. JAMA Netw Open. 2025 04 01; 8(4):e255340.
-
Design and implementation of a Type-2 hybrid, prospective randomized trial of opioid agonist therapies integration into primary care clinics in Ukraine. Contemp Clin Trials. 2024 11; 146:107690.
-
Factors Associated With the Availability of Medications for Opioid Use Disorder in US Jails. JAMA Netw Open. 2024 09 03; 7(9):e2434704.
-
Impact of childhood adversity on acute subjective effects of stimulant and opioid drugs: Evidence from placebo-controlled studies in healthy volunteers. J Psychopharmacol. 2024 11; 38(11):986-997.
-
Buprenorphine Prescribing Characteristics Following Relaxation of X-Waiver Training Requirements. JAMA Netw Open. 2024 08 01; 7(8):e2425999.